Hearing loss affects millions worldwide, yet hearing aids and cochlear implants have major limitations. mRNA-based gene therapy could address the underlying molecular causes, but lipid nanoparticle (LNP) delivery in the inner ear remains underexplored and its biodistribution has not been systematically characterized....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for clinical practice; this is early-stage animal research and human translation remains years away.
mRNA-based gene therapy delivered via lipid nanoparticles represents a promising non-viral strategy for hereditary hearing loss, and understanding inner-ear biodistribution in neonatal models is a critical first step toward future clinical trials.
- 01Lipid nanoparticles (LNPs) used to deliver mRNA into the neonatal mouse inner ear were studied for biodistribution.
- 02Research addresses the limitations of hearing aids and cochlear implants for hereditary hearing loss.
- 03Neonatal timing may be critical given the developmental window for inner ear gene expression.
- 04Study is in-vivo animal research (neonatal mouse model); human applicability is unproven.
- 05Findings lay groundwork for future LNP-based gene therapy clinical development.
mRNA-delivering lipid nanoparticles can be distributed within the neonatal mouse inner ear.
studypartially supportedExisting hearing aids and cochlear implants have limitations for hereditary hearing loss.
opinionsupported- PMID
- 42861365
- DOI
- 10.1016/j.ijpx.2026.100675.
- Journal
- International Journal of Pharmaceutics: X
- Publication type
- research_article
- Evidence level
- na
- Population
- Neonatal mice (animal model for inner ear gene delivery)
- Intervention
- Intracochlear or systemic administration of mRNA-loaded lipid nanoparticles
Primary outcomes
Biodistribution of lipid nanoparticles within the neonatal mouse inner ear